You are here

AVANTGEN INC

Company Information
Address
10151 Pacific Mesa Boulevard Ste 103
SAN DIEGO, CA 92121-4329
United States



Information

UEI: WLNHKNPNT2M7

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. TOPIC 319 PHASE I; RECOMBINANT RABBIT MONOCLONAL ANTIBODIES AS AFFINITY CAPTURES

    Amount: $199,987.00

    Recombinant rabbit monoclonal antibodies as affinity captures for peptides PUBLIC HEALTH RELEVANCE

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health
  2. IGF::OT::IGF OTHER FUNCTIONS SBIR PHASE II, TOPIC 288, RECOMBINANT ANTIBODIES AS AFFINITY CAPTURES

    Amount: $747,441.00

    The objective of this proposed project is to develop recombinant antibodies against 75 cancer-related proteins. In the Phase I study, we have demonstrated that multiple antibody clones could be isolat ...

    SBIRPhase II2012Department of Health and Human Services National Institutes of Health
  3. OTHER FUNCTIONS- RECOMBINANT ANTIBODIES AS AFFINITY CAPTURES

    Amount: $990,779.00

    One of the biggest roadblocks to the translation of basic proteomic discoveries to potential clinical applications is the lack of robust and sensitive reagents that can capture a given protein reprodu ...

    SBIRPhase II2012Department of Health and Human Services National Institutes of Health
  4. A novel approach for developing GPCR subtype specific antibodies

    Amount: $697,427.00

    DESCRIPTION (provided by applicant): Despite the prevalence of serious mental illness, our current understanding of the pathophysiology of mental disorders is limited. In part, this is due to the comp ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
  5. RECOMBINANT ANTIBODIES AS AFFINITY CAPTURES

    Amount: $149,951.00

    Not Available

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  6. DEVELOPMENT OF ALTERNATIVE AFFINITY CAPTURE REAGENTS FOR CANCE

    Amount: $150,000.00

    With the advances in proteomics, thousands of cancer biomarker candidates have been discovered. To fully validate these candidate cancer markers and eventually translate them into clinical use, it is ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  7. Endothelial Lipase: a novel therapeutic target for HDL and atherosclerosis

    Amount: $277,115.00

    DESCRIPTION (provided by applicant): There is mounting evidence indicating that endothelial lipase (EL) plays a key role in the regulation of circulating cholesterol levels by modulating high-density ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  8. RENEWABLE CAPTURES FOR ADDICTION-RELEVANT PROTEINS

    Amount: $750,000.00

    The overall objective of the proposed scope of work for this Phase II contract is to leverage AvantGen's proprietary yeast display technology and synthetic human antibody library to isolate renewable ...

    SBIRPhase II2010Department of Health and Human Services National Institutes of Health
  9. Novel human anti-uPAR antibodies for the treatment of pancreatic cancer

    Amount: $158,025.00

    DESCRIPTION (provided by applicant): Cancers that are typically diagnosed as late-stage, metastatic disease, such as pancreatic cancer, have remained refractory to standard radiation, surgical and che ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
  10. A novel therapeutic antibody for treatment of ischemic stroke.

    Amount: $220,061.00

    DESCRIPTION (provided by applicant): Stroke is the third leading cause of death in the United States. Despite its prevalence, current treatment options are limited and surviving stroke is still associ ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government